Anticancer and Antimicrobial Studies of Dibutyl(hexadecanoyloxy)stannyl Hexadecanoate

This research aimed to develop an effective anticancer and antimicrobial drug. The dibutyl(hexadecanoyloxy)stannyl hexadecanoate was synthesized in a benzene-ethanol medium by azeotropically removing water molecules and was characterized by NMR and FT-IR investigations. An in vitro investigation was performed utilizing the well diffusion technique against Bacillus subtilis MTCC121 (gram-positive) and Pseudomonas aeruginosa 1934 (gram-negative) bacterial strains to evaluate its antibacterial capabilities. After 24 h of incubation, the experimental outcomes were compared to a chloramphenicol-treated control group. In in vitro antibacterial research, the synthesized compound inhibited the development of both Bacillus subtilis MTCC121 (gram-positive) and Pseudomonas aeruginosa 1934 (gram-negative) bacteria. In silico docking tests were carried out using the software package iGemDock v2.1. PDB 1ZJ8 (Mycobacterium tuberculosis NirA protein structure), PDB 1IKQ (wild-type Pseudomonas aeruginosa Exotoxin A), and PDB 3RB9 (Crystal structure of M. tuberculosis beta clamp) were used as docking targets in this research. The synthesized complex interacted well with these PDB files, indicating possible antibacterial activity. Furthermore, the PDB 1M14 tyrosine kinase domain from epidermal growth factor receptor (EGFR) was investigated as a possible anticancer drug. The synthesized complex displayed efficient binding to the tyrosine kinase domain of EGFR, which has been linked to breast, lung, ovarian, and prostate malignancies in the in silico investigation. The complex efficiently prevented EGFR overexpression by preventing protein dimerization. Based on these findings, the complex has a high potential for use as an anticancer drug.